drugset / Trial / NCT04590118
Allogeneic Mesenchymal Stem Cells for the Survivors of Ischemic Stroke Trial (ASSIST)
Phase 1/2
Unknown
60 enrolled
Jiuzhitang Maker (Beijing) Cell Technology Co.,Ltd.
Beijing Tiantan Hospital · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of single injection of it-hMSC in patients with ischemic stroke in a multicenter, blind, randomized, placebo controlled trial
Timeline
- Start
- 2021-04-26
- Primary completion
- 2023-04-01
- Completion
- 2023-08-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | it-hMSC | Cell therapy | 500000 cells/kg | Intravenous |
| Subject | it-hMSC | Cell therapy | 1e+06 cells/kg | Intravenous |
| Subject | it-hMSC | Cell therapy | 2e+06 cells/kg | Intravenous |